MA52939A - Composés inhibiteurs d'oga - Google Patents
Composés inhibiteurs d'ogaInfo
- Publication number
- MA52939A MA52939A MA052939A MA52939A MA52939A MA 52939 A MA52939 A MA 52939A MA 052939 A MA052939 A MA 052939A MA 52939 A MA52939 A MA 52939A MA 52939 A MA52939 A MA 52939A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382455 | 2018-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52939A true MA52939A (fr) | 2021-04-28 |
Family
ID=62784078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052939A MA52939A (fr) | 2018-06-21 | 2019-06-20 | Composés inhibiteurs d'oga |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210130352A1 (fr) |
| EP (1) | EP3810608B1 (fr) |
| JP (1) | JP2021527687A (fr) |
| CN (1) | CN112313231B (fr) |
| AU (1) | AU2019291099A1 (fr) |
| CA (1) | CA3103048A1 (fr) |
| ES (1) | ES2927355T3 (fr) |
| MA (1) | MA52939A (fr) |
| WO (1) | WO2019243533A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913491PA (en) | 2016-12-22 | 2020-03-30 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP3679040B1 (fr) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CA3098574A1 (fr) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| AU2019262599B2 (en) | 2018-05-04 | 2023-10-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012731A (es) | 2018-06-01 | 2021-02-22 | Amgen Inc | Inhibidores de kras g12c y metodos para su uso. |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| MA55136A (fr) | 2018-11-19 | 2022-02-23 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| PE20220504A1 (es) | 2019-05-21 | 2022-04-07 | Amgen Inc | Formas en estado solido |
| AR120456A1 (es) * | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| WO2003009852A1 (fr) * | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Inhibiteurs de tyrosine kinase |
| CN104311563B (zh) * | 2007-11-28 | 2016-12-07 | 达那-法伯癌症研究所 | Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法 |
| CN103864793B (zh) * | 2014-03-12 | 2016-08-17 | 山东大学 | 取代嘌呤-9-乙酰氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用 |
| AU2015308437C1 (en) * | 2014-08-28 | 2020-11-05 | Asceneuron Sa | Glycosidase inhibitors |
| WO2017106254A1 (fr) * | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Inhibiteurs de glycosidase et leurs utilisations |
| AU2017222958B2 (en) * | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
| WO2018055316A1 (fr) * | 2016-09-26 | 2018-03-29 | Centre National De La Recherche Scientifique | Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives |
-
2019
- 2019-06-20 AU AU2019291099A patent/AU2019291099A1/en not_active Abandoned
- 2019-06-20 JP JP2020570881A patent/JP2021527687A/ja active Pending
- 2019-06-20 ES ES19732991T patent/ES2927355T3/es active Active
- 2019-06-20 WO PCT/EP2019/066392 patent/WO2019243533A1/fr active Application Filing
- 2019-06-20 EP EP19732991.5A patent/EP3810608B1/fr active Active
- 2019-06-20 US US17/253,522 patent/US20210130352A1/en not_active Abandoned
- 2019-06-20 CA CA3103048A patent/CA3103048A1/fr active Pending
- 2019-06-20 MA MA052939A patent/MA52939A/fr unknown
- 2019-06-20 CN CN201980041370.0A patent/CN112313231B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2927355T3 (es) | 2022-11-04 |
| EP3810608A1 (fr) | 2021-04-28 |
| EP3810608B1 (fr) | 2022-08-10 |
| CN112313231B (zh) | 2023-05-09 |
| WO2019243533A1 (fr) | 2019-12-26 |
| US20210130352A1 (en) | 2021-05-06 |
| CN112313231A (zh) | 2021-02-02 |
| AU2019291099A1 (en) | 2021-01-07 |
| CA3103048A1 (fr) | 2019-12-26 |
| JP2021527687A (ja) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| MA52948A (fr) | Composés | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA52489A (fr) | Nouveaux composés | |
| MA51669A (fr) | Composés | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA52967A (fr) | Composés antagonistes du pcsk9 | |
| MA53003A (fr) | Composés | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| UA42295S (uk) | Комп'ютер | |
| MA46652A (fr) | Polythérapie pour l'inhibition de c3 | |
| MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| UA42369S (uk) | Комп'ютер | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| DK3737677T3 (da) | Tetrahydroisoquinolinforbindelser | |
| MA52935A (fr) | Composés inhibiteurs d'oga | |
| DK3840596T3 (da) | Sammensætning | |
| MA52936A (fr) | Composés inhibiteurs d'oga | |
| MA52937A (fr) | Composés inhibiteurs d'oga |